Table 2.

Perspectives for colorectal cancer.

Perspectives	Factors
A. Cancer prevention	Lifestyle risks
	Hereditary cancer identification and management
	Public education
B. Identification of early CRC stages	Screening programs (population coverage)
	Improvement of current tests
	New low-invasive methods (liquid biopsies)
C. New prognostic and predictive markers necessary to distinguish suitable patients for current treatment	Patients suitable for neoadjuvant/adjuvant chemotherapy
	High-risk patients where more aggressive approach is applicable
	Predictive markers for targeted therapy
D. Identification of new molecular targets	Anti-tumor immunity activation
	Epigenetic changes
	Role of microbiome
E. Drug development	New effective molecules against identified targets
	Treatment for larger groups of patients (role of immunotherapy)
	Reduced toxicity and side effects of the treatment
F. Faster implication of actual knowledge to the clinical practice	Clinical trials design improvement
	Cost efficiency vs. clinical efficacy acceptable equilibrium
	Suspension of treatment, which has not shown efficacy